Kroeger Christopher A. 4
4 · MapLight Therapeutics, Inc. · Filed May 6, 2026
Research Summary
AI-generated summary of this filing
MapLight Therapeutics (MPLT) CEO Christopher Kroeger Sells 49,744 Shares
What Happened
Christopher A. Kroeger, CEO of MapLight Therapeutics (MPLT), reported multiple open-market sales totaling 49,744 shares for aggregate proceeds of approximately $1,412,235. The reported trades:
- 2026-05-04: 9,136 sh @ $27.50 = $251,240; 5,427 sh @ $28.37 = $153,964; 311 sh @ $29.56 = $9,193; 697 sh @ $30.08 = $20,966.
- 2026-05-05: 9,544 sh @ $28.12 = $268,377; 928 sh @ $29.00 = $26,912.
- 2026-05-06: 8,098 sh @ $28.04 = $227,068; 15,603 sh @ $29.13 = $454,515.
All transactions are recorded as sales (code “S”), which are typically routine dispositions rather than new purchases.
Key Details
- Transaction dates: May 4–6, 2026; Form 4 filed May 6, 2026. Filing appears timely (Form 4s are due within two business days).
- Total shares sold: 49,744; total proceeds: ~$1.41 million.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Notable footnotes: some sales were made pursuant to a Rule 10b5-1 trading plan adopted Dec 29, 2025 (F1); certain shares are held in the C&M Kroeger Nominee Trust (he is co‑trustee) (F10). Several lines report weighted-average prices and disclose that the shares were sold in multiple executions within stated price ranges (F2–F9); the filer will provide per‑price breakouts on request.
Context
These are outright sales (not option exercises or gifts). Sales executed under a 10b5‑1 plan are pre‑arranged and often used to avoid timing questions; they do not, by themselves, imply new negative or positive information about the company. For retail investors, purchases by insiders can be a stronger signal than routine sales; this filing documents liquidity actions by the CEO rather than new accumulation.
Insider Transaction Report
Form 4
Kroeger Christopher A.
DirectorChief Executive Officer
Transactions
- Sale
Voting Common Stock
[F1][F2]2026-05-04$27.50/sh−9,136$251,240→ 1,621,428 total - Sale
Voting Common Stock
[F1][F3]2026-05-04$28.37/sh−5,427$153,964→ 1,616,001 total - Sale
Voting Common Stock
[F1][F4]2026-05-04$29.56/sh−311$9,193→ 1,615,690 total - Sale
Voting Common Stock
[F1][F5]2026-05-04$30.08/sh−697$20,966→ 1,614,993 total - Sale
Voting Common Stock
[F1][F6]2026-05-05$28.12/sh−9,544$268,377→ 1,605,449 total - Sale
Voting Common Stock
[F1][F7]2026-05-05$29.00/sh−928$26,912→ 1,604,521 total - Sale
Voting Common Stock
[F1][F8]2026-05-06$28.04/sh−8,098$227,068→ 1,596,423 total - Sale
Voting Common Stock
[F1][F9]2026-05-06$29.13/sh−15,603$454,515→ 1,580,820 total
Holdings
- 101,190(indirect: See footnote)
Voting Common Stock
[F10]
Footnotes (10)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
- [F10]The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Kristopher L. Hanson, Attorney-in-Fact|2026-05-06